Table 1.
Patient’s characteristic and survival analysis of DFS by clinically important baseline status in the first diagnosed breast cancer and biomarker at the start of the study
| Total N=54 | No. of case (percentage %) | DFS (months) | χ2 | p-value | |
|---|---|---|---|---|---|
|
| |||||
| Median ± SD | Range | ||||
| Age (year) | 0.53 | 0.818 | |||
| ≤50 | 33 (61.1) | 38±7.46 | 0-145 | ||
| >50 | 21 (38.9) | 13±3.43 | 0-120 | ||
| Total | 54 | 21±8.398 | 0-145 | ||
| Tumor grade | 2.235 | 0.327 | |||
| Grade I, II | 37 (68.5) | 21±5.052 | 0-145 | ||
| Grade III | 13 (24.1) | 30±11.234 | 2-73 | ||
| Unknown | 4 (7.4) | 65±28.000 | 12-120 | ||
| Tumor size | 2.737 | 0.254 | |||
| T1 ≤2 | 11 (20.4) | 40±15.276 | 3-107 | ||
| T2 2-≤5 | 26 (48.1) | 21±8.286 | 0-145 | ||
| T3-T4 >5 | 17 (31.5) | 13±6.174 | 0-72 | ||
| Nodal status | 56.533 | <0.001 | |||
| Negative | 15 (27.8) | 21±14.813 | 4-65 | ||
| 1-3 | 13 (24.1) | 42±17.375 | 2-145 | ||
| 4-9 | 13 (24.1) | 40±6.591 | 6-120 | ||
| ≥10 | 9 (16.7) | 12±2.981 | 3-107 | ||
| Primary IV | 4 (7.4) | 0 | 0 | ||
| ER | 0.006 | ||||
| Positive | 30 (55.6) | 41±6.162 | 0-145 | 7.653 | |
| Negative | 24 (44.4) | 12±2.449 | 0-24 | ||
| PR | 0.021 | ||||
| Positive | 27 (50) | 41±5.193 | 0-145 | 5.354 | |
| Negative | 27 (50) | 13±1.731 | 0-73 | ||
| HER2 | 6.486 | 0.011 | |||
| Negative | 27 (50.0) | 38±12.981 | 0-145 | ||
| Positive | 27 (50.0) | 13±1.731 | 0-73 | ||
| Ki67 activity | 4.386 | 0.223 | |||
| Negative | 1 (1.9) | 13 | 13 | ||
| ≤20% | 14 (25.9) | 21±7.951 | 0-145 | ||
| >20% | 33 (61.1) | 14±5.742 | 0-107 | ||
| Unknown | 6 (11.1) | 58±6.736 | 12-120 | ||
| PI3KCA | 0.023 | 0.878 | |||
| WT | 35 (64.8) | 27±10.560 | 0-145 | ||
| MT | 19 (35.2) | 14±4.897 | 0-120 | ||
| PI3KCA p.H1047R | 0.450 | 0.502 | |||
| WT | 43 (79.6) | 22±7.492 | 0-145 | ||
| MT | 11 (20.4) | 13±18.166 | 2-120 | ||
| ERBB1-4 | 2.111 | 0.146 | |||
| WT | 40 (74.1) | 21±5.053 | 0-120 | ||
| MT | 14 (25.9) | 38±28.062 | 2-145 | ||
| PI3KCA+ERBB2 | 2.551 | 0.110 | |||
| WT | 30 (55.6) | 21±6.148 | 0-73 | ||
| MT | 24 (44.4) | 36±17.759 | 0-145 | ||
| TP53 | 1.919 | 0.166 | |||
| WT | 32 (59.3) | 36±12.728 | 0-145 | ||
| MT | 22 (40.7) | 21±4.612 | 2-72 | ||
| Adjuvant CT | 1.881 | 0.597 | |||
| Anthracycline based | 9 (16.7) | 39±26.833 | 4-145 | ||
| Taxol based | 4 (7.4) | 12±21.000 | 0-65 | ||
| A+T | 34 (62.9) | 21±10.788 | 0-120 | ||
| No CT | 3 (5.6) | 14±6.532 | 6-59 | ||
| IV | 4 | 0 | |||
| Adjuvant ET | 17.710 | <0.001 | |||
| No | 24 (44.4) | 12±1.220 | 0-67 | ||
| Yes | 30 (55.6) | 43±6.847 | 2-145 | ||
| DFS (months) | |||||
| Total | 54 | 21±8.398 | 0-145 | ||
| <12 m | 19 (35.2) | ||||
| 12-24 | 9 (16.7) | ||||
| 24-36 | 3 (5.6) | ||||
| >36 | 23 (66.7) | ||||
Note: DFS: disease free survival; ER: estrogen receptor; PR: progesterone receptor; MT: mutation, WT: wild type; A: Anthracycline; T: Taxol; CT: chemotherapy; ET: endocrintherapy; IV: initially advanced disease; If one patients has more than one of same gene mutation but not same site will only count once.